Kaplan-Meier curves of overall survival A) All patients, B) By Culine prognostic risk group, C) By number of metastatic sites and D) By lactate dehydrogenase levels.

<p>Kaplan-Meier curves of overall survival A) All patients, B) By Culine prognostic risk group, C) By number of metastatic sites and D) By lactate dehydrogenase levels.</p

Univariate Analysis of One-year Survival Estimates by Patient and Clinical Characteristics.

<p>Univariate Analysis of One-year Survival Estimates by Patient and Clinical Characteristics.</p

Baseline patient characteristics and clinicopathological variables in 47 adolescents and young adult patients with cancer of unknown primary.

<p>Baseline patient characteristics and clinicopathological variables in 47 adolescents and young adult patients with cancer of unknown primary.</p

Case illustrating use of tissue of origin profiling in poorly differentiated neoplasms.

<p><b>A)</b> CT Abdomen at diagnosis shows a large intrabdominal mass, <b>B)</b> CT Abdomen after 3 cycles of chemotherapy with 5-Fluorouracil paclitaxel, and oxaliplatin (T-FOX) shows progressive disease, <b>C)</b> CT Abdomen after 3 cycles of etoposide, adriamycin and ciplatin (EAP) shows radiographic response <b>D)</b> Trend in tumor marker, CA-125.</p

Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma - Fig 4

<p><b>Kaplan–Meier survival curves showing that low ASS1 expression (ASS1-low) is associated reduced overall survival (<i>p</i> = 0.005, A) and disease-free survival (<i>p</i> = 0.001, B) compared to those whose tumors are ASS1-high in the untreated cohort.</b> (C) and (D) Kaplan–Meier survival curves showing that ASS1-low is associated reduced overall survival (p = 0.04, C), but not disease-free survival (<i>p</i> = 0.13, D) compared to those whose tumors are ASS1-high in the treated cohort.</p

The average immunohistochemical scores of ASS1 expression is significantly lower in treated cohort than that in untreated cohort (<i>p</i> = 0.007).

<p>The average immunohistochemical scores of ASS1 expression is significantly lower in treated cohort than that in untreated cohort (<i>p</i> = 0.007).</p

Multivariate Cox Regression Analysis of Disease-free and Overall Survival in Untreated Group.

<p>Multivariate Cox Regression Analysis of Disease-free and Overall Survival in Untreated Group.</p

Multivariate Cox Regression Analysis of Overall Survival in Treated Group.

<p>Multivariate Cox Regression Analysis of Overall Survival in Treated Group.</p

Univariate Cox Regression Analysis of Disease-free and Overall Survival in Untreated Group.

<p>Univariate Cox Regression Analysis of Disease-free and Overall Survival in Untreated Group.</p

Correlation of ASS1 Expression and Clinicopathologic Parameters in Untreated Group and Treated Groups.

<p>Correlation of ASS1 Expression and Clinicopathologic Parameters in Untreated Group and Treated Groups.</p